Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

34.02 +0.77 (+2.30%)
Streaming Delayed Price Updated: 2:41 PM EDT, Jun 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
From Alvotech
Via GlobeNewswire
News headline image
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
From Alvotech
Via GlobeNewswire
News headline image
Teva to Present at the Goldman Sachs Global Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Present at the BofA Securities Health Care Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics
Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities 
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Releases Q1 2026 Aide Memoire
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Present at the Upcoming Investor Conferences in March
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) 
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.